Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.
Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.
复制标题
妇女健康倡议激素治疗试验干预后阶段的性活动和阴道症状。
DOI：
10.1097/gme.0000000000000994
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Mouton,Charles
中科院分区：
文献类型：
--
作者：
Gass,Margery;Larson,Joseph;Cochrane,Barbara;Manson,JoAnnE;Lane,Dorothy;Barnabei,Vanessa;Ockene,Judith;Stefanick,MarciaL;Mouton,Charles
目的：评估妇女健康倡议雌激素-孕激素治疗(EPT)和雌激素治疗(ET)试验受试者停止口服激素治疗(HT)对性行为、阴道症状和性行为成分的影响。方法：对仍在服用研究药片的患者进行干预后的调查，并同意在试验停止时继续研究。结果：总共有13,902名平均年龄为69.9岁(EPT试验，子宫完好的妇女)和71.7岁(ET试验，有子宫切除史的妇女)的女性接受了调查。干预后性行为发生率前EPT组和安慰剂组差异无统计学意义(36.0%vs34.2%；P=0.37)。曾吸食ET者的性行为比安慰剂者高5.6%(27.6%vs22.0%；P=0.001)。大多数性生活活跃的女性总体上保持着性高潮能力和性满足感。与以前服用安慰剂的人相比，曾经服用EPT的人报告性行为的欲望、性唤醒、性交、高潮和满足感降低的可能性要高10%到12%，并且在停止研究药物后干燥感和排尿困难也会增加(P<；0.001)。与安慰剂使用者相比，前ET使用者更有可能在干预后报告罕见或没有性欲或性唤醒(P<；0.001)。结论：以前被分配到ET组的干预后ET试验参与者比以前被分配到安慰剂组的参与者更有可能报告性行为。停止EPT的女性更有可能报告与阴道和性相关的负面影响。
Objective:To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative.Methods:Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables.Results:In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0% vs 34.2%; P= 0.37). Sexual activity of former ET users was 5.6% higher than placebo users (27.6% vs 22.0%; P= 0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10% to 12% more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P< 0.001). Former ET users were more likely than placebo users to report rare to no desire or arousal postintervention (P< 0.001).Conclusions:Postintervention ET trial participants formerly assigned to ET were significantly more likely to report sexual activity than those formerly assigned to placebo. Women who discontinued EPT were significantly more likely to report negative vaginal and sex-related effects.